Meeting Details - The fifth board meeting of Sannuo Biological Sensor Co., Ltd. was held on June 19, 2025, with all seven directors present [1] - The meeting was convened and chaired by Chairman Li Shaobo, and it complied with the relevant laws and regulations [1] Resolutions Passed - The board approved the proposal not to adjust the conversion price of Sannuo Convertible Bonds downwards, despite the stock price being below 80% of the current conversion price for 15 out of 30 trading days [1][2] - The current conversion price is set at 34.39 CNY per share, with the threshold for adjustment being 27.51 CNY per share [1] Future Considerations - The board decided that if the conversion price adjustment conditions are triggered again within the next six months (from June 20, 2025, to December 19, 2025), no downward adjustment proposal will be made [2] - The next period for potential adjustment will start from December 22, 2025, and the board will follow the necessary procedures if conditions are met [2]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于不向下修正三诺转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、自2025年5月29日至2025年6月19日，三诺生物传感股份有限公司（以下简 称"公司"或"三诺生物"）股票已出现任意连续三十个交易日中至少有十五个 交易日的收盘价低于当期转股价格的80%的情形，触发"三诺转债"转股价格向 下修正条款。 2、公司于2025年6月19日召开第五届董事会第十九次会议，审议并通过《关 于不向下修正三诺转债转股价格的议案》，公司董事会决定本次不向下修正"三 诺转债"转股价格，且自本次董事会审议通过的次一交易日起未来六个月内（即 2025年6月20日至2025年12月19日），如再次触发"三诺转债"转股价格向下修正 条款，亦不提出向下修正方案。 经深圳证券交易所同意，本次可转换公司债券已于2021年1月12日起在深圳证 券交 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-058 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届董事会第十九次会 议于 2025 年 6 月 19 日（星期四）下午 15:30 在公司会议室以现场结合通讯方式 召开。本次会议的通知已于 2025 年 6 月 18 日通过书面或电子邮件方式送达全体 董事。应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人，分别为李少 波先生（兼任总经理）、李心一女士、车宏菁女士、李晖（LI HUI）先生、袁洪 先生、康熙雄先生、陈纪正女士。本次会议由董事长李少波先生召集并主持，公 司监事、高级管理人员列席了会议。会议的召集、召开符合《公司法》及《公司 章程》《公司董事会议事规则》的规定。 二、会议审议情况 本次会议采用现场和通讯表决方式进行表决，经与会董事 ...

Core Insights - The article highlights the increasing trend of diabetes among young people, emphasizing the importance of blood sugar monitoring as a lifestyle choice rather than just a medical necessity [2][8][29] - The demand for blood glucose monitors has surged, driven by a shift in consumer behavior towards health management and preventive care [12][13][22] Industry Overview - The blood glucose monitor market is experiencing rapid growth, with the market size expected to reach 380 billion yuan by 2025, reflecting a compound annual growth rate of nearly 26% [22] - The rise in popularity of blood glucose monitors is attributed to the increasing health awareness among younger generations, particularly the 90s and 00s demographics [12][14] Market Dynamics - The primary consumers of blood glucose monitors are becoming younger, with a shift in purchasing motives from disease treatment to preventive monitoring [13][14] - The market is seeing a significant increase in the sales of dynamic glucose monitors, which are more user-friendly and less invasive compared to traditional finger-prick devices [10][11][19] Competitive Landscape - Domestic companies like Yuyue and Sanofi are emerging as key players in the blood glucose monitoring market, with notable revenue growth in their glucose management solutions [17][18] - The competition is intensifying as more affordable and innovative products enter the market, leading to price reductions of over 50% for some dynamic glucose monitors [19] Consumer Behavior - Young consumers are increasingly purchasing blood glucose monitors not only for themselves but also for their family members, indicating a broader acceptance of health monitoring devices in households [14][15] - Social media platforms like Xiaohongshu are playing a significant role in promoting blood glucose monitors, with trending topics related to health management and product recommendations [3][15] Technological Advancements - The development of continuous glucose monitoring (CGM) devices is revolutionizing the market, providing real-time data without the need for finger pricks [10][19] - The accuracy of these devices is measured by the MARD value, with most products maintaining a range of 7.5% to 9.5%, which is crucial for consumer trust [18][19] Future Trends - The future of the blood glucose monitor market is expected to focus on smart, multifunctional devices that integrate health management features, appealing to the tech-savvy younger generation [21][22] - Companies are also exploring the development of multi-parameter monitoring devices that can track additional health metrics alongside blood glucose levels [20]

Financial Assistance Overview - The company approved a financial assistance of up to 500 million RMB to its subsidiary, Changsha Xinnuo Health Industry Investment Co., Ltd., to meet its funding needs and reduce overall financing costs [1][2] - The financial assistance will be provided for a period of three years starting from the date of approval by the 2023 annual general meeting [1][3] Financial Assistance Progress - On June 16, 2025, the company signed a loan agreement with Changsha Xinnuo Health for 9 million RMB, with a guarantee provided by Mr. Li Shaobo, a shareholder of the subsidiary [2][3] - The loan interest will be calculated based on the actual loan amount at the same rate as similar business bank loans [3][4] Risk Control Measures - The company has implemented risk control measures, including monitoring the use of funds and ensuring that the financial assistance does not exceed the approved limits [4][5] - Mr. Li Shaobo has provided a guarantee for the loan, and the company will charge a usage fee based on the actual loan amount and time, not less than the bank loan rate [5] Cumulative Financial Assistance Amount - As of the announcement date, the total financial assistance provided to Changsha Xinnuo Health amounts to 395 million RMB, representing 11.76% of the company's audited net assets for 2024 [5][6] - After this assistance, the remaining balance of financial assistance provided by the company is 105 million RMB [5]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于向控股子公司提供财务资助的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、财务资助情况概述 三诺生物传感股份有限公司（以下简称"公司"）分别于2024年4月24日召 开第五届董事会第十次会议、第五届监事会第九次会议，于2024年5月21日召开 2023年年度股东大会，审议并通过《关于向控股子公司提供财务资助的议案》， 为解决控股子公司长沙心诺健康产业投资有限公司（以下简称"心诺健康"）资 金使用需求，降低上市公司整体融资成本，在不影响公司正常经营的前提下，同 意公司以不超过5亿元人民币的自有资金向控股子公司心诺健康提供财务资助， 期限为公司2023年年度股东大会审议通过之日起三年，并按实际使用资金以不低 于同类业务同期银行贷款利率与心诺健康结算资金使用费，上述额度在授权期限 内，资金可滚动使用，同时心诺健康其他股东李少波先生按持股比 ...

三诺生物传感股份有限公司的主营业务是血糖监测系统的生产和销售。公司的主要产品是血糖监测系 统、糖尿病营养、护理等辅助产品、血脂检测系统、iPOCT监测系统、糖化血红蛋白检测系统、血压 计、经营品。公司作为血糖监测领域领先企业，先后荣获"国家企业技术中心"、"国家工程研究中 心"、"国家技术创新示范企业"、"国家知识产权优势企业"、"国家科技进步二等奖"和"国家绿色工厂"等 资质。 最新一期业绩显示，2025年一季报，公司实现营业收入10.42亿元，同比2.76%；净利润7211.51万元， 同比-10.90%，销售毛利率48.69%。 6月16日，三诺生物今日收盘22.68元，上涨1.30%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到40.31倍，创48天以来新低，总市值127.98亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三诺生物40.3139.223.87127.98亿行业平均 49.5647.474.64106.50亿行业中值36.1837.862.4148.50亿1英科医疗9.3810.120.83148.24亿2九安医疗 10.1310.250.80171. ...

Group 1 - The event "Industrial and Information Lecture Hall" focused on the digital transformation of the biopharmaceutical industry, with over 100 participants including government officials and industry representatives [1][3] - The event included site visits to Hengxiutang Pharmaceutical Co., Ltd. and Sinocare Inc., where attendees learned about digital transformation experiences [3] - More than 100 small and medium-sized enterprises in Changsha's biopharmaceutical sector are participating in the third batch of transformation trials, creating multiple typical application scenarios and innovative dual-line integration models [3] Group 2 - Hengxiutang Pharmaceutical's digital transformation leader shared insights on the underlying logic and implementation paths of digital transformation, addressing pain points in traditional Chinese medicine manufacturing [3] - The next steps for the industrial system include building a "government-industry-university-research-application" platform to tackle common technologies like AI quality control and drug traceability [3] - The initiative aims to support benchmark enterprises in sharing transformation experiences and encourage personalized intelligent manufacturing scenarios, while also focusing on cultivating interdisciplinary talent through collaboration with universities and research institutions [3]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-056 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： | | | 2、债券代码：123090 债券简称：三诺转债 3、转股价格：34.61元/股 4、转股期限：2021年6月25日至2026年12月20日 5、自2025年5月29日至2025年6月12日，三诺生物传感股份有限公司（以下简 称"公司"或"三诺生物"）股票已有10个交易日的收盘价低于当期转股价格的 80%（即27.69元/股），预计将触发《三诺生物传感股份有限公司创业板向不特定 对象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）规定的 "三诺转债"转股价格向下修正条件。如后续触发转股价格向下修正条件，公司 将根据相关法律法规和《募集说明书》的规定及时履行审议程序和信息披露义务。 敬请广大投资者注意投资风险。 一、可转 ...

特别提示： 三诺生物传感股份有限公司（以下简称"公司"）因实施2024年年度权益分 派，根据《三诺生物传感股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》及《深圳证券交易所创业板上市公司自律监管指南第1号——业务 办理》等相关规定，经向深圳证券交易所申请，公司可转换公司债券（债券代码： 123090；债券简称：三诺转债）自2025年6月5日起至本次权益分派股权登记日（即 2025年6月12日）止暂停转股，具体内容详见公司于2025年6月3日在中国证监会 指定的创业板信息网站披露的《关于权益分派期间三诺转债暂停转股的提示性公 告》（公告编号：2025-051）。 根据相关规定，"三诺转债"将于本次权益分派股权登记日后的第一个交易 日即2025年6月13日（星期五）起恢复转股，敬请"三诺转债"债券持有人留意。 特此公告。 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于三诺转债恢复转股的提示性公告 本公司及董事会全体成员保证信息披露 ...